Repro Med Systems Inc (KRMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Repro Med Systems Inc (KRMD) has a cash flow conversion efficiency ratio of 0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($14.66K) by net assets ($16.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See KRMD equity financing ratio to measure how much of total assets are equity-financed.
Repro Med Systems Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Repro Med Systems Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check KRMD operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Repro Med Systems Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Repro Med Systems Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AIRO Group Holdings, Inc. Common Stock
NASDAQ:AIRO
|
-0.008x |
|
Europen Endustri Insaat Sanayi ve Ticaret A.S.
IS:EUREN
|
0.005x |
|
Studsvik AB
ST:SVIK
|
0.140x |
|
Korea Information & Communications Co. Ltd
KQ:025770
|
-0.057x |
|
Genomictree Inc.
KQ:228760
|
-0.028x |
|
Kizilbuk Gayrimenkul Yatirim Ortakligi AS
IS:KZBGY
|
0.029x |
|
Ador Welding Limited
NSE:ADORWELD
|
0.013x |
|
Petrus Resources Ltd
TO:PRQ
|
0.041x |
Annual Cash Flow Conversion Efficiency for Repro Med Systems Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Repro Med Systems Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see Repro Med Systems Inc (KRMD) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.05 Million | $462.40K | 0.027x | +242.64% |
| 2024-12-31 | $16.81 Million | $-319.72K | -0.019x | +92.09% |
| 2023-12-31 | $20.35 Million | $-4.89 Million | -0.240x | -39.33% |
| 2022-12-31 | $31.33 Million | $-5.40 Million | -0.173x | -45.79% |
| 2021-12-31 | $36.50 Million | $-4.32 Million | -0.118x | -475.63% |
| 2020-12-31 | $36.16 Million | $-743.32K | -0.021x | -172.05% |
| 2019-12-31 | $11.24 Million | $320.62K | 0.029x | -82.72% |
| 2018-12-31 | $8.96 Million | $1.48 Million | 0.165x | +40.73% |
| 2017-12-31 | $7.67 Million | $899.91K | 0.117x | +336.21% |
| 2016-12-31 | $6.68 Million | $-331.62K | -0.050x | -117.56% |
| 2015-12-31 | $6.77 Million | $1.91 Million | 0.283x | +114.76% |
| 2014-12-31 | $6.27 Million | $826.10K | 0.132x | -28.37% |
| 2013-12-31 | $5.19 Million | $954.39K | 0.184x | +2.05% |
| 2012-12-31 | $4.36 Million | $784.79K | 0.180x | +14.10% |
| 2011-12-31 | $3.55 Million | $560.60K | 0.158x | -67.34% |
| 2010-12-31 | $2.13 Million | $1.03 Million | 0.483x | +30.72% |
| 2009-12-31 | $1.03 Million | $382.30K | 0.370x | -50.62% |
| 2008-12-31 | $705.09K | $528.18K | 0.749x | +483.59% |
| 2007-12-31 | $-602.26K | $117.61K | -0.195x | -247.35% |
| 2006-12-31 | $-645.83K | $-85.59K | 0.133x | -45.57% |
| 2005-12-31 | $-569.82K | $-138.75K | 0.243x | -51.70% |
| 2004-12-31 | $-380.26K | $-191.69K | 0.504x | +150.37% |
| 2003-12-31 | $-173.46K | $-34.92K | 0.201x | -32.76% |
| 2002-12-31 | $61.19K | $18.32K | 0.299x | +315.55% |
| 2001-12-31 | $337.38K | $-46.87K | -0.139x | +29.35% |
| 2000-12-31 | $694.45K | $-136.56K | -0.197x | -234.46% |
| 1999-12-31 | $657.91K | $96.22K | 0.146x | +171.80% |
| 1998-12-31 | $540.00K | $-110.00K | -0.204x | -15.43% |
| 1997-12-31 | $1.87 Million | $-330.00K | -0.176x | -266.50% |
| 1996-12-31 | $2.17 Million | $230.00K | 0.106x | -- |
About Repro Med Systems Inc
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropath… Read more